The Electron Microscopy Shared Resource (EMSR) is an institutional research resource laboratory providing specimen preparation, microscopy and digital imaging services to investigators within the Mayo Clinic. Centrally located in the Guggenheim Research Building on the 14th floor on the Rochester Campus, the shared resource is fully equipped to offer standard transmission (TEM) and scanning (SEM) electron microscopy. The shared resource also performs X-ray probe microanalysis, electron tomography, cryoultramicrotomy, and immuno-gold labeling procedures. Costs are recovered primarily through recharges to investigator budgets and through institutional support. The facility has been an important shared resource of the Mayo Clinic Cancer Center (MCCC) since 2004. The requested budget will support, in part, current EMSR services utilized by cancer center members, and partially offset the resource's projected yearly operational expenditures of $1,202,039. Usage of the EMSR by MCCC members account for an average utilization of -20% of the EMSR's services and operations during the period from 2003 to 2007. The budget requested for the next five year period will support 8% of the resource's expenses and operations provided to MCCC members. The EMSR provides additional value to Mayo Clinic Cancer Center members in three ways: First the EMSR is continuously developing and implementing new techniques and procedures in electron microscopy directed specifically to the individual needs of MCCC Members. New methods under development include electron tomography, cryo ultramicroscopy, 3-D image analysis, electron diffraction and microwave processing. Second, MCCC member projects are given first priority in the laboratory's specimen handling queue. And finally, MCCC member projects are directly subsidized through discounts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-35
Application #
7945053
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-17
Project End
2014-02-28
Budget Start
2009-04-17
Budget End
2010-02-28
Support Year
35
Fiscal Year
2009
Total Cost
$101,890
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7

Showing the most recent 10 out of 1129 publications